|
 Clostridium Perfringens
Type A Toxoid
Swine Vaccine
Swine veterinarians and producers now have a vaccine to help
battle neonatal diarrhea, which can cause lower weaning weights
and directly affect survival in the nursery and grow/finish phase.
Clostridium Perfringens Type A Toxoid, the first
vaccine to help control C. perfringens Type A diseases,
is available under a conditional license by the USDA for use only
in swine.
Clostridium perfringens Type A naturally resides in the
swine intestine, but it remains one of the leading causes of diarrhea
in neonatal pigs. Pathogenic C. perfringens Type A bacteria
produce destructive exotoxins, which cause yellow-to-white pasty
diarrhea – usually within the first week of life. Mortality
typically is low, but the impacts on performance are seen throughout
the pig’s lifetime.
| PRODUCT
HIGHLIGHTS |
The
first conditionally licensed C. perfringens Type
A vaccine for swine
- Development of a Type A vaccine is tough, but Novartis scientists have developed
a way to produce consistent toxoid levels and meet efficacy standards for
conditional licensure |
Aids
in the control of disease syndromes caused by the alpha
toxin of C. perfringens
- Yellow-to-white
pasty neonatal diarrhea can wreak havoc on performance |
Field
studies demonstrate product safety
- Administration to 1,364 bred gilts or sows and 590 feeder pigs demonstrated
safety of product when used according to label directions |
| Product
should only be used in swine |
How
much to give
- Administer 2 mL intramuscularly. Booster in 2-4 weeks. Revaccinate as recommended
by your veterinarian. |
| Package
size: 50 doses |
|
